The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Qtrilmet

850/2.5/5 milligram(s) Modified-release tablet

AstraZeneca ABEU/1/19/1401/001-014

Main Information

Trade NameQtrilmet
Active SubstancesSaxagliptin
METFORMIN HYDROCHLORIDE
Dapagliflozin
Strength850/2.5/5 milligram(s)
Dosage FormModified-release tablet
Licence HolderAstraZeneca AB
Licence NumberEU/1/19/1401/001-014

Group Information

ATC CodeA10BD25 metformin, saxagliptin and dapagliflozin

Status

Authorised/WithdrawnWithdrawn
Withdrawn Date14/08/2020
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back